Skip to content
Screener

Pacira BioSciences, Inc. PCRX Price / earnings

Price / earnings at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
24.5×-2.2×

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$1.02B+1.3%
Enterprise value$1.29B+21.7%
P/S1.4×0.0×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

market cap/net income=178.1×

Based on the most recent quarter.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026. Open the filing →

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871

FAQ

What is Pacira BioSciences, Inc.'s price / earnings?
Pacira BioSciences, Inc. (PCRX) reported price / earnings of 178.1× in Q1 2026.
What is the long-term trend for Pacira BioSciences, Inc.'s price / earnings?
Over 2 years (2020 to 2025), Pacira BioSciences, Inc.'s price / earnings has grown at a 194.0% compound annual growth rate (CAGR), from 18.3× to 158.3×.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about Pacira BioSciences, Inc.'s price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude